Former CEO Mark Iwicki was paid $906,642 in fiscal year 2025, ↓ down 39.2% from fiscal year 2024 (SEC filing 0001829126-26-010384 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$3,476,972 Todd Bazemore total, FY2025 Former Interim Chief Executive Officer, President and Chief Operating Officer — highest-paid officer; CEO Mark Iwicki: $906,642 | — CEO (Mark Iwicki) pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Ask our research desk, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Todd Bazemore | $489,112 | $585,450 | $76,053 | $2,262,211 | $0 | $0 | $64,146 | $3,476,972 |
| Former Interim Chief Executive Officer, President and Chief Operating Officer | ||||||||
| Kim Brazzell | 420,000 | 522,000 | 76,053 | 285,040 | 0 | 0 | 55,081 | 1,358,174 |
| Former Head of Research and Development and Chief Medical Officer | ||||||||
| Mary Reumuth | 438,962 | 475,550 | 76,053 | 285,040 | 0 | 0 | 47,002 | 1,322,608 |
| Former Chief Financial Officer | ||||||||
| Mark Iwicki | 111,866 | 0 | 166,413 | 627,467 | 0 | 0 | 896 | 906,642 |
| Former Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Todd Bazemore | $3,476,972 | $949,550 | — | ↑ +2,527,422 |
| Kim Brazzell | 1,358,174 | 920,687 | — | ↑ +437,487 |
| Mary Reumuth | 1,322,608 | 778,269 | — | ↑ +544,339 |
| Mark Iwicki | 906,642 | 1,491,187 | — | ↓ −584,545 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read KALA BIO, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper KALA reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses KALA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Mark Iwicki | RSU | 52,969 | — | $29,451 |
| Todd Bazemore | Option | 34,842 | 7.53 | — |
| Todd Bazemore | Option | 7,533 | 7.05 | — |
| Mary Reumuth | Option | 10,677 | 7 | — |
| Mark Iwicki | RSU | 22,100 | — | 12,288 |
| Todd Bazemore | RSU | 14,040 | — | 15,260 |
| Todd Bazemore | Option | 165,000 | 11.22 | — |
| Todd Bazemore | RSU | 16,236 | — | 9,027 |
| Mark Iwicki | RSU | 13,903 | — | 7,730 |
| Mary Reumuth | RSU | 12,051 | — | 6,700 |
| Todd Bazemore | RSU | 10,100 | — | 5,616 |
| Mary Reumuth | RSU | 10,100 | — | 5,616 |
| Mark Iwicki | RSU | 9,534 | — | 5,301 |
| Todd Bazemore | RSU | 4,334 | — | 2,410 |
| Mark Iwicki | RSU | 2,584 | — | 1,437 |
| Todd Bazemore | RSU | 4,268 | — | 2,373 |
| Mary Reumuth | RSU | 3,176 | — | 1,766 |
| Mark Iwicki | Option | 33,594 | 7 | — |
| Mary Reumuth | RSU | 3,067 | — | 1,705 |
| Mark Iwicki | RSU | 2,450 | — | 1,362 |
| Todd Bazemore | RSU | 794 | — | 441 |
| Mary Reumuth | RSU | 512 | — | 285 |
| Mark Iwicki | Option | 79,437 | 14.56 | — |
| Mark Iwicki | Option | 76,698 | 7.53 | — |
| Mary Reumuth | Option | 34,842 | 7.53 | — |
| Mark Iwicki | Option | 5,450 | 4.3 | — |
| Todd Bazemore | Option | 24,349 | 14.56 | — |
| Mary Reumuth | Option | 18,072 | 14.56 | — |
The company's compensation program is designed to motivate employees to achieve annual goals based on strategic, financial, and operating performance objectives, while equity grants are intended to create a strong link to long-term performance, foster an ownership culture, and align executive interests with stockholders through time-based and performance-based vesting features.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew I. KovenIndependent | $96,298 | $13,115 | $24,628 | — | — | $134,041 |
| Howard B. RosenIndependent | 75,000 | 10,535 | 19,595 | — | — | 105,130 |
| Mark IwickiIndependent | 68,139 | 10,535 | 19,595 | — | — | 98,269 |
| C. Daniel MyersIndependent | 67,500 | 10,535 | 19,595 | — | — | 97,630 |
| Marjan FaridIndependent | 67,500 | 10,535 | 19,595 | — | — | 97,630 |
| Gregory D. PerryIndependent | 44,837 | 10,535 | 19,595 | — | — | 74,967 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $419,274 |
| Equity awards (grant-date value) | $65,790 |
| All other compensation | $0 |
| Total cost of the board | $485,064 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | KALA BIO, Inc. | 2025 | Mark Iwicki | $111,866 | $166,413 | $627,467 | $0 | $906,642 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Todd Bazemore | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Executive Compensation”. As printed: 3,476,972. Filing ↗machine: r4 · c26 · span 234810–234819 |
| 2 | Section 01, Kim Brazzell | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Executive Compensation”. As printed: 1,358,174. Filing ↗machine: r7 · c26 · span 241398–241407 |
| 3 | Section 01, Mary Reumuth | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Executive Compensation”. As printed: 1,322,608. Filing ↗machine: r10 · c26 · span 247968–247977 |
| 4 | Section 01, Mark Iwicki | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Executive Compensation”. As printed: 906,642. Filing ↗machine: r1 · c26 · span 228261–228268 |
| 5 | Section 08, Andrew I. Koven | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Director Compensation”. As printed: 134,041. Filing ↗machine: span 517663–517670 |
| 6 | Section 08, Howard B. Rosen | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Director Compensation”. As printed: 105,130. Filing ↗machine: span 520365–520372 |
| 7 | Section 08, Mark Iwicki | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Director Compensation”. As printed: 98,269. Filing ↗machine: span 515855–515861 |
| 8 | Section 08, C. Daniel Myers | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Director Compensation”. As printed: 97,630. Filing ↗machine: span 518564–518570 |
| 9 | Section 08, Marjan Farid | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Director Compensation”. As printed: 97,630. Filing ↗machine: span 516763–516769 |
| 10 | Section 08, Gregory D. Perry | DEF 14A | 2026-09-24 | 0001829126-26-010384 | Section “Director Compensation”. As printed: 74,967. Filing ↗machine: span 519465–519471 |
| 11 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 12 | Section 09b board cost (computed) | Computed | — | — | Cash 419,274 + equity 65,790 + all other 0 = 485,064, summed across the director compensation table rows.machine: formula: Σ = 485,064 |
| 13 | KALA BIO, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-09-24 | 0001829126-26-010384 | CEO total compensation as printed in KALA BIO, Inc.'s own proxy. As printed: 906,642. Filing ↗machine: r1 · c26 · span 228261–228268 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat